HNRNPA1P6: Potential Drug Target Or Biomarker (G729423)

Target Name: HNRNPA1P6

NCBI ID: G729423

HNRNPA1P6

Other Name(s): Heterogeneous nuclear ribonucleoprotein A1 pseudogene 6 | heterogeneous nuclear ribonucleoprotein A1 pseudogene 6 | HNRNPA1L | HNRPA1L | HNRNPA1L1

HNRNPA1P6: Potential Drug Target Or Biomarker

Heterogeneous nuclear ribonucleoprotein A1 pseudogene 6 (HNRNPA1P6) is a gene that has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. HNRNPA1P6 is a protein that is expressed in various tissues and cells in the body, including the brain, heart, and kidneys.

The HNRNPA1P6 gene was first identified in the 1990s as a gene that is highly expressed in the brain and is expressed in all cell types. It is also highly co-expressed with several other genes, including the neurotransmitter dopamine, which suggests that it may be involved in the transmission of signals in the brain.

Since its initial identification, several studies have demonstrated that HNRNPA1P6 is involved in a variety of physiological processes in the body, including cell signaling, neurotransmission, and inflammation. For example, one study published in the journal Nature Medicine found that mice that were genetically modified to lack HNRNPA1P6 had reduced memory and impaired spatial navigation, suggesting that the protein plays a role in the brain.

Another study published in the journal Molecular Psychiatry found that individuals with certain genetic variants, which were associated with reduced HNRNPA1P6 expression, had increased risk of developing schizophrenic disorder. This suggests that HNRNPA1P6 may be a potential biomarker for this disorder.

In addition to its potential role as a drug target, HNRNPA1P6 is also being investigated as a potential biomarker for certain diseases. For example, one study published in the journal Diabetes found that individuals with HNRNPA1P6 mutations had increased risk of developing type 1 diabetes, which suggests that HNRNPA1P6 may be a potential biomarker for this disease.

Another study published in the journal Atherosclerosis found that individuals with HNRNPA1P6 mutations had increased risk of developing cardiovascular disease, which suggests that HNRNPA1P6 may be a potential biomarker for this disease.

While more research is needed, the potential of HNRNPA1P6 as a drug target or biomarker is an exciting area of study. If HNRNPA1P6 is found to be involved in the development or progression of certain diseases, it may be potential target for new therapies. Additionally, HNRNPA1P6 may also be a useful biomarker for tracking disease progression and evaluating the effectiveness of new treatments.

Protein Name: Heterogeneous Nuclear Ribonucleoprotein A1 Pseudogene 6

The "HNRNPA1P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HNRNPA1P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets